Carlotz Inc
Change company Symbol lookup
Select an option...
LOTZ Carlotz Inc
TSLA Tesla Inc
INN Summit Hotel Properties Inc
NCNO nCino Inc
FISK Empire State Realty OP LP
RMD Resmed Inc
BST BlackRock Science and Technology Trust
MPW Medical Properties Trust Inc
UWHR Uwharrie Capital Corp
ESI Element Solutions Inc

Consumer Discretionary : Specialty Retail |
Company profile

CarLotz, Inc., formerly Acamar Partners Acquisition Corp., operates vehicle consignment and retail remarketing business. The Company provides its corporate vehicle sourcing partners and retail sellers of used vehicles with the ability to access the retail sales channel. It operates a technology-enabled buying, sourcing and selling model that offers an omni-channel and selection of vehicles, while allowing for an end-to-end electronic commerce interface that enables buying and selling. The Company's Retail Remarketing technology provides its corporate vehicle sourcing partners with real-time performance metrics and data analytics, along with custom business intelligence reporting that enables price and vehicle triage optimization between the wholesale and retail channel. The Company offers its products and services to corporate vehicle sourcing partners, retail sellers of used vehicles and retail customers seeking to buy used vehicles.

Closing Price
Day's Change
-0.13 (-6.74%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Section 32 Raises $740 Million Venture Fund

8:14 am ET November 4, 2021 (PR Newswire) Print

Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

"I'm so pleased that Nina has joined this team and I look forward to what this growing group will achieve together," commented Bill Maris, founder of Section 32. "What a privilege it is to close this fourth fund, and to thus have the continued opportunity to try to use capital as a lever to accelerate the profound positive impact technology can have on healthcare and humanity."

The closing of Fund 4 brings assets under management for Section 32 to over $1.8B. To-date, Section 32 has made investments in more than 70 companies including Coinbase (Nasdaq: COIN), Crowdstrike (Nasdaq: CRWD), Relay Therapeutics (NASDAQ: RLAY), Thrive Earlier Detection (Acquired by Exact Sciences NASDAQ: EXAS), and Vir Biotechnology (NASDAQ: VIR). Section 32 has made eight investments from Fund 4 following an initial close of the fund in July 2021.

Since its inception in 2017, Section 32 has grown to 16 people, including four managing partners: Bill Maris, Michael Pellini, M.D., Steve Kafka, Ph.D., and Andy Harrison, with offices in San Diego, Silicon Valley and Boston, MA. The team's cumulative career experience includes contributing to more than 130 company exits (through acquisition or public offerings) and helping to build and finance more than 50 companies with valuations in excess of $1 billion.

With the closing of Fund 4, Section 32 added Nina Labatt to its team as its chief operating officer and chief financial officer. Nina brings more than two decades of experience to her new role and is recognized as an industry expert leading finance and operations in venture capital and private equity.

"I'm delighted to join the team at Section 32 at this exciting time in the firm's growth," commented Nina Labatt. "I look forward to collaborating with the team to continue building world-class operations and finance functions that support our investing efforts."

Most recently, Nina served as chief operating officer and general partner at Trinity Ventures, where she managed finance, marketing, data analytics, human resources, and legal for the firm. She also led internal strategic initiatives, structured and executed investment transactions with the investing team and participated in the firm's fundraising efforts. Previously, Ms. Labatt served as managing director, Private Equity Services for Silicon Valley Bank, as well as chief financial officer for Health Evolution Partners. Earlier in her career, Ms. Labatt was an investment banker for Goldman Sachs and Montgomery Securities. Ms. Labatt received a bachelor's degree in economics and a master's degree in international policy studies from Stanford University. She received her MBA from Harvard Business School. She was a founding member of the Northern California board of directors for the CFO Leadership Council and previously served as chairperson of the board of directors of VCBC, a non-profit association for finance professionals in venture capital.

About Section 32Section 32 is a venture capital fund investing at the frontiers of technology and healthcare. Founded by Bill Maris, the team has vast experience building iconic companies. The firm's goal is to improve the human condition by accelerating the discovery, development and distribution of important technologies and life-saving medicines. Section 32 invests across the entirety of technology and life sciences. This includes software, cybersecurity, advanced communications and computation, space, climate change related technologies, machine learning, artificial intelligence, biotechnology, therapeutics, advanced diagnostics, precision medicine, genomics and more. For more information, please visit

View original content to download multimedia:

SOURCE Section 32

comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.